- MedPharm and Tergus Pharma have merged, enhancing their CDMO capabilities.
- Michael Kane is appointed CEO of the combined MedPharm, with Patrick Walsh continuing as Executive Chairman.
MedPharm, a global topical and transdermal Contract Development and Manufacturing Organization (CDMO), has merged with Tergus Pharma, forming an end-to-end CDMO with enhanced scientific, clinical trial manufacturing, and commercial production capabilities. The newly combined organization will continue under the MedPharm name.
The merger, announced today, positions the business as a global leader in delivering comprehensive drug development and manufacturing services for topical and transepithelial pharmaceuticals. Michael Kane, the former CEO of Tergus Pharma, will take on the role of CEO of the new MedPharm, while Patrick Walsh remains the Executive Chairman.
“This strategic partnership is an exciting opportunity to deliver extensive pharmaceutical product development resources,” commented Michael Kane. “With our cutting-edge topical GMP facility, we can seamlessly meet our customers’ commercial production needs.”
The merger leverages both companies’ strengths to provide commercial production and serialization alongside existing formulation development, in vitro testing, and clinical manufacturing. The company’s GMP manufacturing facility in Durham, NC, will also develop and manufacture hormone-based and highly potent drugs.
Patrick Walsh noted, “Pharma clients have been seeking a reliable, integrated service offering for their ophthalmic, topical, and transdermal projects. This merger creates an immediate option with two organizations already well-positioned in the industry.”
Tergus lead investor Great Point Partners will retain a significant minority ownership stake in the newly combined MedPharm, while private equity firms Ampersand Capital Partners and Bourne Partners Strategic Capital will assume majority ownership.
 Overview of outsourcing trends 
